Press release from Companies

Publicerat: 2021-04-16 14:00:54

Spermosens AB (publ): Spermosens receives Intention to Grant from the European Patent Office

Spermosens AB today announces that the company has received an Intention to Grant from the European Patent Office (EPO) for its patent application directed to a biosensor and its use in In Vitro Fertilization (IVF). The next step in the process is a formal EPO approval, which provides a patent protection until 2039.

The patent application, with application number no. 19759542.4, for which the EPO has issued an "Intention to Grant communication", refers to the company’s biosensor product and its use for, e.g., detecting and quantifying sperm binding function, diagnosis of male infertility, and selection of sperms suitable for In Vitro Fertilization (IVF) purposes.

The communication for the EPO means that the patent office intends to grant Spermosens’ patent application after completion of a number of administrative steps. The patent, when granted, provides protection for Spermosens’ product in Europe until 2039.

Spermosens has corresponding patent applications pending in Australia, Brazil, Canada, China, Eurasia (including Russia), Hong Kong, Israel, India, Japan, Mexico, New Zealand, Singapore, South Korea, South Africa, and the USA.

"Spermosens which is currently in the final stage of a listing on Spotlight, aims to provide an important technology for couples undergoing IVF treatment. With the EPO Intention to Grant communication in Europe, Spermosens has obtained important patent protection for its product in the important home market, John Lempert", CEO of Spermosens AB says.

"We are very happy for this success in our continuous efforts to build value in our patent portfolio. It is a great team achievement deriving from the close collaboration between our brilliant development team, and our quality IP partner HØIBERG", Kushagr Punyani, CSO and co-founder of Spermosens says.

For further information, please contact:
John Lempert, VD
+46 (0)76-311 40 91

This information is such that Spermosens AB is obligated to disclose pursuant to the EU Market Abuse Regulation. The information was published, through the agency of the contact persons mentioned above, at 2:00 pm on 16 April 2021.

Spermosens AB (publ)

Spermosens was founded in 2018 and develops medical devices for male infertility to individualize and adapt In Vitro fertilization treatments. The technology is based on an independent research group's discovery of the so-called JUNO protein in human egg cells in 2018. Spermosens’ first patent-applied product consists mainly of two components: a measuring instrument with associated software and a disposable chip. The measuring instrument analyzes sperm that is applied to the chip and finds out if they can bind to the egg cell via the JUNO protein.

Spermosens grundades 2018 och utvecklar en teknologi för manlig fertilitetsdiagnostik och fertilitetsbehandling. Teknologin grundar sig på två oberoende forskargruppers upptäckt av det så kallade JUNO-proteinet i äggceller; på möss 2014 och i mänskliga äggceller 2018. Spermosens produkt består huvudsakligen av två komponenter; ett mätinstrument med tillhörande programvara, samt engångschip. Mätinstrumentet analyserar spermierna som applicerats på chipen och utläser om de kan binda till äggcellen via JUNO-proteinet.

Läs mer hos Cision
Läs mer om Spermosens AB (publ)